Clinical Practice GuidelinesEASL Clinical Practice Guidelines: Management of hepatitis C virus infection
Under a Creative Commons license
open access
Abbreviations
AE
adverse event
ALT
alanine aminotransferase
BMI
body mass index
BOC
boceprevir
BT
viral breakthrough
CPGs
Clinical Practice Guidelines
CYP3A4
cytochrome p450 3A4
DAA
direct-acting antiviral
DVR
delayed virological response
EIA
enzyme immunoassays
EPO
erythropoietin
eRVR
extended rapid virological response
EVR
early virological response
G-CSF
granulocyte colony stimulating factor
GRADE
Grading of Recommendations Assessment, Development and Evaluation
HBV
hepatitis B virus
HCC
hepatocellular carcinoma
HCV
hepatitis C virus
IDU
intravenous/injecting drug use
IFN
interferon
IU
international units
LSM
liver stiffness measurement
LT
liver transplant
OST
opiate/opioid substitution treatment/therapy
PegIFN/RBV
pegylated interferon-α and ribavirin
PI
protease inhibitor
PWID
people who inject drugs
RVR
rapid virological response
SCAR
severe cutaneous adverse reaction
SVR
sustained virological response
TSH
thyroid stimulating hormone
TVR
telaprevir
Cited by (0)
Contributors: David Mutimer (Coordinator), Alessio Aghemo, Helmut Diepolder, Francesco Negro, Geert Robaeys, Stephen Ryder, Fabien Zoulim.
Reviewers: Markus Peck, Antonio Craxi, Michael Fried, Stefan Zeuzem.
© 2013 European Association for the Study of the Liver. Published by Elsevier B.V.